Imricor Medical Systems, Inc. (ASX:IMR)
Australia · Delayed Price · Currency is AUD | Market Cap | 466.25M +0.9% |
| Revenue (ttm) | 173.57K -84.0% |
| Net Income | -53.94M |
| EPS | -0.18 |
| Shares Out | 358.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 351,252 |
| Open | 1.300 |
| Previous Close | 1.330 |
| Day's Range | 1.285 - 1.320 |
| 52-Week Range | 1.275 - 2.250 |
| Beta | 0.54 |
| Analysts | Strong Buy |
| Price Target | 2.95 (+127.08%) |
| Est. Earnings | Nov 9, 2026 |
About Imricor Medical Systems
Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States, Europe, and the Middle East. The company’s products include Vision-MR Ablation Catheter 2.0, a MR-compatible cardiac ablation catheter; Vision-MR Diagnostic Catheter, a MR-compatible diagnostic catheter; NorthStar mapping system, a real-time, high-resolution soft tissue imaging of MRI to guide and visualize procedures with except... [Read more]
Financial Performance
In 2025, Imricor Medical Systems's revenue was $292,309, a decrease of -69.53% compared to the previous year's $959,424. Losses were -$25.32 million, -14.73% less than in 2024.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for IMR stock is "Strong Buy." The 12-month stock price target is $2.95, which is an increase of 127.08% from the latest price.
News
Imricor Medical Systems Earnings Call Transcript: H1 2026
U.S. commercial launch commenced with first customers and strong regulatory momentum, including four FDA clearances and expanded product compatibility. Revenue remains modest as clinical trial sites transition to commercial use, but a robust balance sheet and new business verticals position the company for accelerated growth.
Imricor Medical Systems Earnings release: H1 2026
Imricor Medical Systems released its H1 2026 earnings on August 9, 2026, summarizing the period's financial results.
Imricor Medical Systems Slides: H1 2026
Imricor Medical Systems has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 9, 2026.
Imricor Medical Systems Transcript: AGM 2026
The meeting reviewed significant clinical and regulatory milestones, highlighted a strengthened financial position, and approved key board elections, incentive plans, and auditor ratification. No questions were raised, and voting results will be released to the ASX.
Imricor Medical Systems Slides: FY 2026
Imricor Medical Systems has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 7, 2026.
Imricor Medical Systems Slides: Investor presentation
Imricor Medical Systems has posted slides in relation to its latest quarterly earnings report, which was published on May 3, 2026.
Imricor Medical Systems Earnings release: Q1 2026
Imricor Medical Systems released its Q1 2026 earnings on April 27, 2026, summarizing the period's financial results.
Imricor Medical Systems Earnings Call Transcript: H2 2025
Major regulatory and clinical milestones achieved, including first-in-human MRI-guided VT ablation and FDA clearance for NorthStar. Revenue declined due to trial-related non-revenue procedures, but commercial readiness and pipeline growth position the company for significant expansion as approvals progress.
Imricor Medical Systems Annual report: H2 2025
Imricor Medical Systems has published its H2 2025 annual report on February 24, 2026.
Imricor Medical Systems Slides: H2 2025
Imricor Medical Systems has posted slides in relation to its H2 2025 quarterly earnings report, which was published on February 24, 2026.
Imricor Medical Systems Earnings release: H2 2025
Imricor Medical Systems released its H2 2025 earnings on February 24, 2026, summarizing the period's financial results.
Imricor Medical Systems Earnings release: Q4 2025
Imricor Medical Systems released its Q4 2025 earnings on January 27, 2026, summarizing the period's financial results.